Listen

Description

Send us a text

Dave brings his analysis of the Q3 Eli Lilly earnings call, and how it relates to the future of access to obesity medicine. Also there is an important clarification on the Zepbound savings card that you should not miss.

#Zepbound #Mounjaro #Tirzepatide

Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

🤝 Visit Our Sponsors!
OTPLinks.com

Decoding GLP-1 Book
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4

MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro

BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join

👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen

WATCH MORE!
📺 We're Live M/W/F at 11 central: onthepen.tv

📲 Contact Me: dave@onthepen.com

Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.